Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir Suppliers & Bulk Manufacturers

Available Forms: Tablet

Available Strengths: Ombitasvir 12.5 mg / Paritaprevir 75 mg / Ritonavir 50 mg (tablet)+ Dasabuvir 250 mg (tablet)

Reference Brands: Viekira Pak® (US); Viekirax® + Exviera® (EU)

Category: Hepatitis

Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir is available in Tablet and strengths such as Ombitasvir 12.5 mg / Paritaprevir 75 mg / Ritonavir 50 mg (tablet)+ Dasabuvir 250 mg (tablet). Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description:

Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir is a fixed-dose combination therapy used in the treatment of chronic Hepatitis C genotype 1. Marketed as Viekira Pak® in the US and Viekirax® + Exviera® in the EU, this regimen includes four direct-acting antivirals that target multiple stages of the HCV replication cycle. It offers a non-interferon-based treatment, often in combination with ribavirin. EMA and FDA approved, it’s a key option for B2B pharmaceutical partners sourcing branded and generic HCV therapies. Suitable for hospital, retail, and tender supply in regulated and semi-regulated markets. Available in tablet form with clearly defined daily dosing.